Growth Factor News and Research

RSS

Regeneron second-quarter total revenues increase to $115.9 million

Regeneron Pharmaceuticals, Inc. announced financial and operating results for the second quarter of 2010. The Company reported a net loss of $25.5 million, or $0.31 per share (basic and diluted), for the second quarter of 2010 compared with a net loss of $14.9 million, or $0.19 per share (basic and diluted), for the second quarter of 2009.

28 Jul 2010

New study reveals potential role of TGF-β1 in kidney disease

Fibrosis in the kidney is one of the key causes of progressive renal failure. High levels of the inflammatory molecule TGF-β1 in the kidney tubules due to tissue damage can cause fibrosis as well as nephron degeneration, resulting in loss of kidney function. To clarify the mechanisms regulating TGF-β1-mediated renal fibrosis, Koesters et al expressed high levels of TGF-β1 in renal tubules of mice. Nephron degeneration in this system was mediated by decomposition of the tubular cells. These data suggest that TGF-β1 may play a novel role in cell death of renal cells, thus contributing to renal fibrosis.

28 Jul 2010

Scientists unveil new biomarkers for stroke, coronary heart disease

Analysis of blood protein data from the Women's Health Initiative cohorts has revealed new biomarkers for stroke and coronary heart disease (CHD). Research published in BioMed Central's open access journal Genome Medicine found that beta-2 microglobulin (B2M) levels were significantly elevated in postmenopausal women with CHD, and insulin-like growth factor binding protein 4 (IGFBP4) was strongly associated with stroke.

28 Jul 2010

AVEO's initiation of AV-299 Phase 2 trial for lung cancer triggers $750,000 milestone payment to XOMA

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced receipt of a $750,000 milestone payment under its collaboration with AVEO Pharmaceuticals, Inc.. The milestone payment resulted from AVEO's recent initiation of a Phase 2 clinical trial to evaluate its AV-299 antibody for the treatment of non-small cell lung cancer. AV-299 is a humanized antibody to hepatocyte growth factor (HGF).

26 Jul 2010

GRB7 gene drives an aggressive form of breast cancer, researchers find

Oregon Health & Science University Knight Cancer Institute researchers found that the GRB7 gene drives an aggressive form of breast cancer and acts independently of the HER-2 gene, known to be a stimulator of breast cancer growth. Isolating the role of this gene could ultimately help fine-tune a patient's treatment and enable physicians to provide a more accurate prognosis.

23 Jul 2010

GCSF administration can reduce side effects of cancer neurobastoma in children

Children given a hormone growth factor alongside chemotherapy for the aggressive cancer neuroblastoma are less likely to suffer a potentially deadly side-effect, according to a major international study published today (Tuesday) in the Journal of Clinical Oncology.

21 Jul 2010

Acorda Therapeutics awarded $1M C-TRIP grant to support research on GGF2

Acorda Therapeutics, Inc. today announced the National Heart, Lung, and Blood Institute has awarded a $1 million Cardiac Translational Research Implementation Program grant to support research on Glial Growth Factor 2, a novel investigational agent for the treatment of patients with heart failure under development at Acorda.

20 Jul 2010

Thymosin beta 4 improves neurological functional outcome after embolic stroke: Researchers

RegeneRx Biopharmaceuticals, Inc. today announced a research team from the Henry Ford Hospital in Detroit, MI, reported that Thymosin beta 4, administered to rats after embolic stroke, improved neurological functional outcome compared to control animals.

20 Jul 2010

Cetuximab recommended for colorectal cancer tumors without mutation in KRAS gene

In a report published in the July 2010 issue of the American Society for Clinical Oncology Post, new recommendations on the use of the drug cetuximab have been issued after officials halted enrollment in a phase III clinical trial in patients with spread of colon cancer into regional lymph nodes whose tumors had been surgically removed.

17 Jul 2010

Evotec to acquire DeveloGen

Evotec AG today announced the signing of a definitive agreement to acquire DeveloGen, a biopharmaceutical company engaged in the discovery of novel therapeutic approaches for the treatment of metabolic and endocrine disorders, for up to €14m in shares plus performance-related deferred payments (earn-out).

15 Jul 2010

SANUWAVE Health introduces orthoPACE device in Europe

SANUWAVE Health, Inc., an emerging medical technology company focused on the development and commercialization of non-invasive, biological response activating devices in the regenerative medicine area, reports the European launch of the orthoPACE device intended for use in orthopedic, trauma and sports medicine indications following CE mark approval last month.

14 Jul 2010

BioInvent reports net revenues of SEK 63.1M for January - June 2010 period

BioInvent reached an important milestone when the results of a phase II trial of TB-402 following orthopaedic surgery, were reported in May. The data showed that TB-402 is statistically better at preventing thrombosis than enoxaparin, the current standard treatment. Supported by these good results, BioInvent and the company's partner, ThromboGenics, will now prioritise securing a development partner for the programme to ensure that the necessary resources is in place to take the product candidate to the market.

14 Jul 2010

Brookhaven Science Associates, BioSET receive U.S. patent for tissue regeneration technology

Brookhaven Science Associates, the company that manages the U.S. Department of Energy's Brookhaven National Laboratory, and Biosurface Engineering Technologies, Inc. of Rockville, Maryland, have been issued a U.S. patent for an improved second-generation technology for designing synthetic peptides that are important for tissue regeneration.

14 Jul 2010

Idera announces issuance of patents for synthetic immune modulatory oligonucleotides targeted to TLRs

Idera Pharmaceuticals, Inc. today announced the issuance of patents covering compositions and methods of using its synthetic immune modulatory oligonucleotides targeted to Toll-like receptors (TLRs). The Company's intellectual property portfolio currently contains over 500 patents and patent applications worldwide and includes claims for TLR-targeted compounds, second-generation antisense chemistry, and oral delivery of certain oligonucleotides.

8 Jul 2010

FDA grants Angion Biomedica's BB3 therapeutic Fast Track and Orphan Drug product designations

Angion Biomedica Corp., a biopharmaceutical company dedicated to the discovery and development of novel therapeutics that enhance quality of life, eradicate disease and save lives by modulating the body's protective, reparative and regenerative systems, announced today that its lead therapeutic BB3 was accepted into the Fast Track program of the U.S. Food and Drug Administration (FDA) and has also been designated an Orphan Drug product by FDA.

7 Jul 2010

New blood test eliminates need for surgical lung biopsy for LAM diagnosis

Researchers at the University of Cincinnati (UC) and Cincinnati Children's Hospital Medical Center have found that a certain blood test can successfully identify lymphangioleiomyomatosis (LAM) in some patients, eliminating the need for surgical lung biopsy to make a diagnosis.

6 Jul 2010

New asthma therapy shows promise for patients who do not respond to steroid treatments

A new nonsteroidal, anti-inflammatory therapy made from a human protein significantly decreases disease signs of asthma in mice, opening the possibility of a new asthma therapy for patients who do not respond to current steroid treatments. Results of this therapy in an animal model were presented at The Endocrine Society's 92nd Annual Meeting in San Diego.

2 Jul 2010

Pre-clinical data of BiTE antibody technology published in PNAS

Micromet, Inc., today announced the publication of pre-clinical data in the Proceedings of the National Academy of Sciences, demonstrating the potency of new product candidates based on the Company's proprietary BiTE antibody technology. BiTE antibodies are a new class of agents designed to harness a patient's T cells to kill cancer cells.

1 Jul 2010

InNexus develops IXS312 small protein fragment as topical therapy for AMD, diabetic retinal dysplasia

InNexus Biotechnology Inc., a drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL™) technology, today announced that it has developed IXS312(VEGF), an antibody fragment with activity against the growth factor VEGF for planned use in ocular treatments.

30 Jun 2010

Oxygen can combat wrinkle formation by reducing UVB damage

It's no secret that UVB radiation from the sun causes wrinkles. However, a Japanese study published in the American Journal of Physiology—Regulatory, Integrative and Comparative Physiology (http://ajpregu.physiology.org/) indicates that oxygen may help combat the formation of wrinkles by lessening tissue damage done by UVB rays.

30 Jun 2010

Growth Factor News and Research

Regeneron second-quarter total revenues increase to $115.9 million

New study reveals potential role of TGF-β1 in kidney disease

Scientists unveil new biomarkers for stroke, coronary heart disease

AVEO's initiation of AV-299 Phase 2 trial for lung cancer triggers $750,000 milestone payment to XOMA

GRB7 gene drives an aggressive form of breast cancer, researchers find

GCSF administration can reduce side effects of cancer neurobastoma in children

Acorda Therapeutics awarded $1M C-TRIP grant to support research on GGF2

Thymosin beta 4 improves neurological functional outcome after embolic stroke: Researchers

Cetuximab recommended for colorectal cancer tumors without mutation in KRAS gene

Evotec to acquire DeveloGen

SANUWAVE Health introduces orthoPACE device in Europe

BioInvent reports net revenues of SEK 63.1M for January - June 2010 period

Brookhaven Science Associates, BioSET receive U.S. patent for tissue regeneration technology

Idera announces issuance of patents for synthetic immune modulatory oligonucleotides targeted to TLRs

FDA grants Angion Biomedica's BB3 therapeutic Fast Track and Orphan Drug product designations

New blood test eliminates need for surgical lung biopsy for LAM diagnosis

New asthma therapy shows promise for patients who do not respond to steroid treatments

Pre-clinical data of BiTE antibody technology published in PNAS

InNexus develops IXS312 small protein fragment as topical therapy for AMD, diabetic retinal dysplasia

Oxygen can combat wrinkle formation by reducing UVB damage

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

How microplastics and bacteria interact to drive antibiotic resistance

Latest News